Nicole Lamanna, investigator with New York-Presbyterian/Columbia University Medical Center was highlighted recently in Cure Today by Kristie L. Kahl.  Ms. Kahl notes that Dr. Lamanna reports that time-limited treatment could be a new wave of research in the treatment of chronic lymphocytic leukemia (CLL).  Ms. Kahl refers to a recent OncLive interview where Lamanna refers to work with the 3 MURANO trial, designed to evaluate the combination of Venclexta (venetoclax) and Rituxan (rituximab) compared with bendamustine plus rituximab (BR) in patients with CLL. Lamanna believes that time-limited treatments may be a strategy to drive down costs given there could be a sub-set of patients with CLL where this could work.  Follow the link for the entire story.

Lead Research/Investigator

Nicole Lamanna


Pin It on Pinterest